Chinese Thoracic Oncology Group (CTONG) and OrigiMed, a medical science and technology company, have unveiled a new clinical trial sharing platform to provide better clinical benefits for patients across the country.

The CTONG-OrigiMed platform will build on CTONG’s clinical experience and OrigiMed’s next generation sequencing expertise. It will offer information on different types of complex clinical cases.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

This sharing cooperation is expected to facilitate better precision medicine clinical trials for cancer.

OrigiMed CEO Dr Kai Wang said: “With more genes sequenced and the continuous progress made in precision medicine, clinical guidance for gene classification and pan-cancer precision medicine may be made available to achieve real individualised medical care.

“It is our hope that the CTONG-OrigiMed platform can unite Chinese and foreign experts to develop more effective precision medicine clinical trials and solutions in fighting against cancer.”

The platform has been unveiled at a summit organised by OrigiMed and sponsored by the Chinese Thoracic Oncology Group (CTONG) and the International Cholangiocarcinoma Research Network (ICRN).

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Involving more than 300 experts, the summit focused on immunotherapy, targeted therapy and precision medicine.

During the discussion, OrigiMed announced various new discoveries for cancer patients in China, including immunotherapy dataset, gene fusions distribution, Dr Groundhog Big Data Platform, along with a NGS lung cancer and breast cancer medical insurance upgrading project.

Combination of the new discoveries with clinical cases is expected to help guide clinical treatment.

According to the China National Cancer Center data, the country has the highest new cancer cases in the world. More than 4.2 million people are being newly diagnosed with the disease each year.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact